Frontiers in Immunology | |
Advances in immunotyping of colorectal cancer | |
Immunology | |
Shuwen Han1  Yinhang Wu1  Jing Zhuang1  Zhanbo Qu1  Xi Yang1  | |
[1] Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China;Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China;Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China; | |
关键词: colorectal cancer; immunotherapy; immune subtype; tumor immune microenvironment; colorectal cancer subtypes; | |
DOI : 10.3389/fimmu.2023.1259461 | |
received in 2023-07-17, accepted in 2023-09-22, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.
【 授权许可】
Unknown
Copyright © 2023 Wu, Zhuang, Qu, Yang and Han
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311143705822ZK.pdf | 6264KB | download |